5 Severely immunodeficient NOG-EXL mice allow for humanization and development of a human glioblastoma-derived tumor microenvironment

BackgroundCellular immunotherapy has resulted in tremendous therapeutic advances across liquid tumors. However, for solid tumors, including glioblastoma (GBM), significant limitations still exist in successfully translating immune-based adoptive cell therapeutics from the bench to the clinic. The ma...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal for immunotherapy of cancer Ročník 11; číslo Suppl 1; s. A5
Hlavní autoři: Binder, Zev, Lamrani, Lamia, Secreto, Anthony, Skuli, Nicholas, Jacobson, Moriah, Assenmacher, Charles-Antoine, Willis, Elinor, Radaelli, Enrico, O’Rourke, Donald, Alanio, Cecile, Nasrallah, Maclean
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BMJ Publishing Group Ltd 01.11.2023
BMJ Publishing Group LTD
BMJ Publishing Group
Témata:
Brain cancer
Flow cytometry
Immunotherapy
Regular and Young Investigator Award Abstracts
Tumors
ISSN:2051-1426
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:BackgroundCellular immunotherapy has resulted in tremendous therapeutic advances across liquid tumors. However, for solid tumors, including glioblastoma (GBM), significant limitations still exist in successfully translating immune-based adoptive cell therapeutics from the bench to the clinic. The majority of preclinical in vivo GBM models either use human cell lines grown in immunodeficient animals or syngeneic tumors grown in immunocompetent animals. Both approaches lack critical immune components of the tumor microenvironment (TME), thus inherently limiting the ability to adequately model immunotherapies.MethodsHere, we demonstrate the ability of hematopoietic stem cells (HSCs) from a GBM patient to successfully engraft in the severely immunodeficient NOG-EXL mouse strain and generate a patient-derived immune system. Mouse brains, with and without tumors, were evaluated by immunohistochemistry and flow cytometry.ResultsIntraosseous injections of a low number (10,000) of CD34+ HSCs, obtained from a bone marrow draw from the patient at the time of tumor resection, resulted in an average of 20% human CD45+ cells in peripheral blood 17 weeks post-transplant. GBM organoids, established from the same patient, were implanted intracranially at Week 18 and allowed to grow for 5 weeks without significant clinical evidence of graft-vs-host disease or macrophage activation syndrome. Immunohistochemical and flow cytometry analyses of mouse brains, with and without tumors, revealed infiltration of human-derived, CD45+/CD33+ cells, in proximity to the tumor engraftment site.ConclusionsThese results demonstrate the ability of patient-obtained CD34+ HSCs to engraft and form a TME in severely immunodeficient mice. Subsequent work will focus on the differences between autologous and allogeneic humanized tumor-bearing mice in the context of the originating tumor. Additional future work will focus on testing cellular therapies directed towards the relevant areas of the autologous model.
Bibliografie:SITC 38th Annual Meeting (SITC 2023) Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:2051-1426
DOI:10.1136/jitc-2023-SITC2023.0005